Insmed, Inc. $INSM Shares Sold by Kingdon Capital Management L.L.C.

Key Points

• Kingdon Capital Management L.L.C. reduced its stake in Insmed, Inc. by 4.4% during the first quarter, now holding approximately 215,000 shares valued at about $16.40 million.
• Insmed recently reported earnings with a loss per share of ($1.70), which missed the consensus estimate, despite a year-over-year revenue increase of 18.9%.
• Several analysts have raised their price targets for Insmed, with a consensus price target of $132.57 and a rating of "Moderate Buy" from 16 analysts.

Kingdon Capital Management L.L.C. trimmed its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 4.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 215,000 shares of the biopharmaceutical company's stock after selling 10,000 shares during the quarter. Insmed makes up 1.7% of Kingdon Capital Management L.L.C.'s portfolio, making the stock its 6th biggest position. Kingdon Capital Management L.L.C. owned 0.12% of Insmed worth $16,402,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. lifted its position in shares of Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 221 shares during the last quarter. Elequin Capital LP bought a new position in shares of Insmed in the 4th quarter worth about $28,000. NBC Securities Inc. bought a new position in shares of Insmed in the 1st quarter worth about $49,000. Versant Capital Management Inc lifted its position in shares of Insmed by 546.3% in the 1st quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 590 shares during the last quarter. Finally, Signaturefd LLC lifted its position in shares of Insmed by 60.0% in the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock worth $66,000 after buying an additional 325 shares during the last quarter.

Insmed Trading Down 1.2%

Shares of Insmed stock traded down $1.80 during trading on Wednesday, hitting $143.50. The stock had a trading volume of 2,493,986 shares, compared to its average volume of 2,809,975. The stock has a 50 day simple moving average of $112.13 and a 200 day simple moving average of $88.41. The company has a market capitalization of $30.33 billion, a PE ratio of -25.13 and a beta of 0.97. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $146.84.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The firm had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business's revenue was up 18.9% on a year-over-year basis. During the same period last year, the business earned ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. On average, research analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. HC Wainwright raised their price target on shares of Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. JPMorgan Chase & Co. raised their price target on shares of Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 20th. Morgan Stanley raised their price target on shares of Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. Stifel Nicolaus raised their price target on shares of Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Finally, Bank of America raised their price target on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. Sixteen equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $134.79.

Insiders Place Their Bets

In other news, CFO Sara Bonstein sold 58,400 shares of Insmed stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the transaction, the chief financial officer directly owned 73,505 shares of the company's stock, valued at $7,546,758.35. This trade represents a 44.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Roger Adsett sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the sale, the chief operating officer owned 105,637 shares of the company's stock, valued at approximately $13,477,168.46. This represents a 19.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 512,927 shares of company stock valued at $51,227,401 over the last 90 days. 3.00% of the stock is owned by corporate insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.